Therametrics : RELIEF THERAPEUTICS Holding AG announces today that it has received the final cash settlement related to last month’s capital increase.

RELIEF THERAPEUTICS Holding AG announces today that it has received the final cash settlement related to last month's capital increase.

Zurich, Switzerland, 26 August 2016

RELIEF THERAPEUTICS Holding AG ('Relief', 'the Company') announces today that it has received the cash payment of approx. CHF 2 million that GEM Global Yield Fund LLC SCS committed to make in relation to the business combination that was completed on 18 July 2016.

Raghuram Selvaraju, Chairman, states: 'Receipt of this cash commitment allows Relief to move forward with its clinical development plans and to continue its strategy of growth through strategic business combinations. In addition to the potential acquisition of FirstString Research announced last month, the company will continue efforts to leverage its proprietary DRR2.0 platform by exploring potential spin-off scenarios for its legacy drug discovery business.'

About Relief Therapeutics Holding AG

RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (already in Phase III) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck-Serono, a division of the global established pharmaceutical firm Merck KGaA, and has been the subject of multiple clinical trials and over €100 million in total capital investment. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Zurich, Switzerland.

For further information, please visit the Relief website atwww.relieftherapeutics.com or contact investor relations at:

Relief Therapeutics Holding AG
Investor Relations
Dr. Raghuram Selvaraju
Tel: +41 44 723 59 59
investors@relieftherapeutics.com

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning Relief Therapeutics Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Relief Therapeutics Holding AG is providing this communication as of this date and does not undertake to update any forward looking statements contained herein as a result of new information, future events or otherwise